Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
INNOVAR vs COLYTE-FLAVORED
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Innovar is a combination of fentanyl (mu-opioid receptor agonist) and droperidol (butyrophenone antipsychotic that blocks dopamine D2 receptors in the CNS, producing sedation and antiemetic effects).
Colyte is an osmotic laxative that induces diarrhea by retaining water in the colon through non-absorbable polyethylene glycol (PEG) and electrolytes, resulting in bowel cleansing.
Neuroleptanalgesia for surgical and diagnostic procedures,Adjunct to general anesthesia
Colonoscopy preparation,Bowel cleansing prior to colorectal surgery,Bowel preparation for barium enema
2-5 m L (droperidol 2.5-5 mg and fentanyl 0.05-0.1 mg) IM/IV every 1-2 hours as needed for neuroleptanalgesia; surgical anesthesia: initial 1 m L/10 kg IM or slow IV, then 0.5 m L increments.
4 liters orally as a single dose or in divided doses for colonoscopy preparation, or 1 liter orally every 10-15 minutes until 4 liters are consumed.
Droperidol: terminal t1/2 2.2–2.5 h (infants 4.5 h). Fentanyl: terminal t1/2 3–7 h (mean ~4 h) in adults; prolonged in elderly (up to 16 h) and hepatic impairment.
Not applicable; the drug acts locally in the gastrointestinal tract without significant systemic absorption. For the small fraction absorbed, a terminal elimination half-life of approximately 0.5-1 hour is estimated, but clinical relevance is negligible.
Fentanyl: CYP3A4 to norfentanyl; Droperidol: CYP3A4 and CYP1A2 to multiple metabolites.
Polyethylene glycol (PEG) is not significantly metabolized; it is excreted unchanged in feces.
Droperidol: ~75% renal as metabolites, ~22% biliary/fecal. Fentanyl: primarily renal as metabolites (85%), ~9% fecal.
Primarily eliminated in feces (≥95%) as intact drug via the gastrointestinal tract. Minimal systemic absorption; renal excretion accounts for <1% of the administered dose.
Fentanyl: ~80–85% bound to albumin and α1-acid glycoprotein. Droperidol: ~85–90% bound to albumin and α1-acid glycoprotein.
Negligible (<5%) due to minimal systemic absorption; no specific binding proteins identified.
Fentanyl: Vd 3–5 L/kg (large distribution to tissues, slow elimination). Droperidol: Vd 1.5–2 L/kg (moderate distribution).
Not meaningful due to negligible systemic absorption. The small fraction absorbed distributes primarily in extracellular fluid; a theoretical Vd would be low (<0.2 L/kg), but not clinically relevant.
Fentanyl: IV 100%; transdermal 92% (after depot formation); transmucosal ~50% (buccal) to 70% (nasal); oral <30% due to first-pass. Droperidol: IV 100%; IM ~85% (well absorbed).
Oral bioavailability is <1% due to minimal gastrointestinal absorption; the drug acts locally within the intestinal lumen.
e GFR >60 m L/min: no adjustment; e GFR 30-60: reduce dose by 25-50% due to fentanyl accumulation; e GFR <30: avoid or use with extreme caution, reduce dose by ≥50%, monitor for respiratory depression.
Use with caution in patients with GFR <30 m L/min/1.73 m2; consider alternative bowel preparation. No specific dose adjustment defined.
Child-Pugh A: reduce dose by 25%; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated due to impaired fentanyl metabolism and increased sedation risk.
No specific adjustment for Child-Pugh class A or B; use with caution in severe hepatic impairment (Child-Pugh C) due to risk of fluid and electrolyte disturbances.
Not FDA-approved for pediatric use; limited data: 0.1 m L/kg (droperidol 0.125 mg/kg + fentanyl 0.0025 mg/kg) IM/IV as single dose; max 1.5 m L. Contraindicated in neonates.
Not recommended for use in children; safety and efficacy not established.
Reduce initial dose by 50-75% (e.g., 0.5-1 m L IM/IV); titrate cautiously; increased risk of hypotension, respiratory depression, and prolonged sedation; monitor renal function.
Use with caution; monitor for fluid and electrolyte imbalances, renal function, and volume status. Consider lower dose or split-dose regimen.
Risk of respiratory depression, especially in elderly, debilitated, or opioid-naive patients; risk of QT prolongation and torsade de pointes with droperidol, including at recommended doses.
There is no FDA black box warning for Colyte.
Monitor respiratory function; avoid in patients with bradycardia, electrolyte abnormalities, or QT prolongation; risk of hypotension, neuroleptic malignant syndrome, and extrapyramidal symptoms.
Risk of aspiration and esophageal perforation in patients with impaired gag reflex or altered consciousness,Electrolyte disturbances (e.g., hypernatremia, hypokalemia) in patients with renal impairment or dehydration,Cardiac arrhythmias in patients with electrolyte imbalances or QT prolongation,Colonic mucosal erosions or ulcerations with repeated use,Not for use in patients with gastrointestinal obstruction, perforation, or ileus
Hypersensitivity to fentanyl, droperidol, or components; known QT prolongation; concurrent MAOIs; severe respiratory depression; myasthenia gravis.
Gastrointestinal obstruction,Gastric retention,Bowel perforation,Toxic colitis,Toxic megacolon,History of severe electrolyte abnormalities,Known hypersensitivity to any component
Avoid grapefruit juice as it may increase fentanyl levels via CYP3A4 inhibition. No specific food restrictions for droperidol. Maintain adequate hydration to prevent hypotension, but monitor for fluid overload if cardiac compromise.
Only clear liquids are allowed during bowel preparation. Avoid milk, cream, soups with solid ingredients, red or purple liquids, and alcohol. Solid food should be avoided at least 2 hours before starting the solution. No food interactions with the drug itself; dietary restrictions are for the procedure.
First trimester: Risk of congenital malformations, including cardiac and neural tube defects, associated with droperidol exposure. Second and third trimesters: Risk of extrapyramidal symptoms, neuroleptic malignant syndrome, and neonatal withdrawal. Fentanyl component may cause fetal respiratory depression and intrauterine growth restriction. Use only if maternal benefit outweighs fetal risk.
Category C: Not associated with major malformations; limited data in pregnancy. No known teratogenicity; use only if clearly needed.
Fentanyl and droperidol are excreted in breast milk. Fentanyl M/P ratio approximately 0.2–0.4. Potential for sedation and respiratory depression in the infant. Avoid breast-feeding for 24 hours after administration. Discard milk during this period.
Excretion unknown; likely minimal systemic absorption. No M/P ratio available. Use with caution.
No established dose adjustments for pregnancy. Increased clearance of fentanyl in third trimester may require higher doses for analgesic effect. Lower doses of droperidol recommended due to increased volume of distribution and prolonged effects. Use lowest effective dose and monitor for excessive sedation and hypotension.
No dosage adjustment required; monitor for hypovolemia due to increased plasma volume.
Innovar (droperidol + fentanyl) is a neuroleptanalgesic combination; monitor for respiratory depression, hypotension, and extrapyramidal symptoms. Droperidol prolongs QTc interval; avoid in patients with electrolyte disturbances or on QT-prolonging drugs. Fentanyl is a potent mu-opioid agonist; naloxone reversal may be needed. Onset of analgesia is rapid (<2 min IV), duration 30-60 min; droperidol's sedative effect lasts 2-4 hours. Use with caution in elderly, hypovolemic, or compromised patients.
Colyte-Flavored (PEG-3350 and electrolytes) is a colonic lavage solution used for bowel preparation prior to colonoscopy. Ensure adequate hydration: patients must consume all 4 liters (or split-dose regimen). Concurrent use of other laxatives or enemas is generally not needed. In patients with impaired gag reflex, renal insufficiency, or electrolyte abnormalities, use with caution. Monitor for bloating, nausea, and aspiration risk. Avoid use in GI obstruction, toxic colitis, or megacolon.
You may feel drowsy and lightheaded; avoid driving or operating machinery for 24 hours.,Report any difficulty breathing, slow or shallow breathing, or severe dizziness immediately.,Avoid alcohol and other sedatives while taking this medication.,Inform your doctor if you have a history of heart rhythm problems, low potassium, or low magnesium.,This drug can cause involuntary muscle movements or restlessness; notify your healthcare provider if these occur.
Do not add any other ingredients to the solution.,Chill the solution before drinking to improve palatability.,Drink the entire volume over the prescribed period; do not eat solid foods until after the procedure.,Expect frequent, watery bowel movements; stay near a toilet.,Take other medications at least 1 hour before starting the solution, except as directed by your doctor.,Stop drinking the solution 2-3 hours before the procedure.,If severe bloating, abdominal pain, or vomiting occurs, pause and resume later.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about INNOVAR vs COLYTE-FLAVORED, answered by our medical review team.
INNOVAR is a Antipsychotic (Butyrophenone) that works by Innovar is a combination of fentanyl (mu-opioid receptor agonist) and droperidol (butyrophenone antipsychotic that blocks dopamine D2 receptors in the CNS, producing sedation and antiemetic effects).. COLYTE-FLAVORED is a Osmotic Laxative that works by Colyte is an osmotic laxative that induces diarrhea by retaining water in the colon through non-absorbable polyethylene glycol (PEG) and electrolytes, resulting in bowel cleansing.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between INNOVAR and COLYTE-FLAVORED depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of INNOVAR is: 2-5 m L (droperidol 2.5-5 mg and fentanyl 0.05-0.1 mg) IM/IV every 1-2 hours as needed for neuroleptanalgesia; surgical anesthesia: initial 1 m L/10 kg IM or slow IV, then 0.5 m L increments.. The standard adult dose of COLYTE-FLAVORED is: 4 liters orally as a single dose or in divided doses for colonoscopy preparation, or 1 liter orally every 10-15 minutes until 4 liters are consumed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between INNOVAR and COLYTE-FLAVORED in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. INNOVAR is classified as Category C. First trimester: Risk of congenital malformations, including cardiac and neural tube defects, associated with droperidol exposure. Second and third trimesters: Risk of extrapyramid. COLYTE-FLAVORED is classified as Category C. Category C: Not associated with major malformations; limited data in pregnancy. No known teratogenicity; use only if clearly needed.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.